A personal initiative for women's health: To challenge the Women's Health Initiative

Gynecological Endocrinology

Volumn 16, Issue 4, 2002, Pages 255-257

  Genazzani, A R ^a   Gambacciani, M ^b  

^a UNIVERSITY OF PISA   (Italy)

^b Menopause Clinic   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

BREAST CANCER; CANCER RISK; CLINICAL TRIAL; DRUG EFFECT; EDITORIAL; FRACTURE; HEALTH; HEALTH HAZARD; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0036693287     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.16.4.255.257     Document Type: Editorial

References (11)

1. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
2. Failure of estrogen plus progestin therapy for prevention
3. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer
4. Hormone replacement therapy: The perspectives for the 21st century. Cardiovascular disease and hormone replacement therapy
5. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women
6. Low-dose hormone replacement therapy: Effects on bone
7. Personal perspective on low-dosage estrogen therapy for postmenopausal women
8. Is low-dose hormone replacement therapy for postmenopausal women efficacious and desirable?
9. Hormone replacement therapy: The benefits in tailoring the regimen and dose
10. Heart and estrogen/progestin replacement study follow-up (HERS II): Part 1. Cardiovascular outcomes during 6.8 years of hormone therapy
11. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)